Are active dwell positions always necessary in the ring/ovoids channel of the cervical applicator in the intracavitary-interstitial brachytherapy of cervical cancer?

被引:0
作者
Frohlich, Georgina [1 ,2 ]
Vizkeleti, Julia [1 ]
Nguyen, Anhhong Nhung [1 ]
Polgar, Csaba [1 ,3 ]
Takacsi-Nagy, Zoltan [1 ,3 ]
Major, Tibor [1 ,3 ]
机构
[1] Natl Inst Oncol, Ctr Radiotherapy, Budapest, Hungary
[2] Eotvos Lorand Univ, Dept Biophys, Fac Nat Sci, Budapest, Hungary
[3] Semmelweis Univ, Dept Oncol, Fac Med, Budapest, Hungary
关键词
cervical cancer; ring activation; ring applicator; Venezia applicator; interstitial brachytherapy; GUIDED ADAPTIVE BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; RADIATION-THERAPY; AMERICAN BRACHYTHERAPY; MRI; RADIOTHERAPY; POINT; RECOMMENDATIONS; FEASIBILITY;
D O I
10.5114/jcb.2023.124399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare dosimetric parameters of brachytherapy (BT) treatment plans made with or without active source positions of the ring/ovoid (R/O) applicator in locally advanced cervical cancer patients. Material and methods: Sixty patients with cervical cancer without vaginal involvement were selected for the study, who received intra-cavitary/interstitial BT. For each patient, two plans with and without active source dwell positions in R/O were created, using the same dose-volume constraints. EQD2 total doses from external beam and BT of target volumes and organs at risk (OARs) between the competing plans were compared. Results: There was no significant difference in the dose of high-risk clinical target volume (HR-CTV) and gross tumor volume (GTV) between the plans with inactive vs. active R/O. The mean D98 of intermediate-risk clinical target volume (IR-CTV) was significantly lower with inactive R/O; however, the GEC-ESTRO (EMBRACE II study) and ABS criteria were fulfilled in 96% in both plans. There was no difference in dose homogeneity, but conformity of the plans with inactive R/O was higher. Doses to all OARs were significantly lower in plans without R/O activation. While all the plans without R/O activation fulfilled the recommended dose criteria for OARs, it was less achievable with R/O activation. Conclusions: Inactivation of R/O applicator results in similar dose coverage of the target volumes with lower doses to all OARs, as activation of R/O in cervix cancer patients when HR-CTV does not extend to R/O applicator. The use of active source positions in R/O shows worse performance regarding the fulfilment of the recommended criteria for OARs.
引用
收藏
页码:48 / 56
页数:9
相关论文
共 45 条
  • [41] American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy
    Viswanathan, Akila N.
    Beriwal, Sushil
    De Los Santos, Jennifer F.
    Demanes, D. Jeffrey
    Gaffney, David
    Hansen, Jorgen
    Jones, Ellen
    Kirisits, Christian
    Thomadsen, Bruce
    Erickson, Beth
    [J]. BRACHYTHERAPY, 2012, 11 (01) : 47 - 52
  • [42] American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles
    Viswanathan, Akila N.
    Thomadsen, Bruce
    [J]. BRACHYTHERAPY, 2012, 11 (01) : 33 - 46
  • [43] Vizkeleti Julia, 2018, Magy Onkol, V62, P249
  • [44] Combined intracavitary and interstitial brachytherapy of cervical cancer using the novel hybrid applicator Venezia: Clinical feasibility and initial results
    Walter, Franziska
    Maihoefer, Cornelius
    Schuettrumpf, Lars
    Well, Justus
    Burges, Alexander
    Ertl-Wagner, Birgit
    Mahner, Sven
    Belka, Claus
    Gallwas, Julia
    Corradini, Stefanie
    [J]. BRACHYTHERAPY, 2018, 17 (05) : 775 - 781
  • [45] Comparison of computed tomography with magnetic resonance imaging for imaging-based clinical target volume contours in cervical cancer brachytherapy
    Zolciak-Siwinska, Agnieszka
    Kowalczyk, Adam
    Sikorska, Katarzyna
    Bijok, Michal
    Michalski, Wojciech
    Gruszczynska, Ewelina
    [J]. BRACHYTHERAPY, 2018, 17 (04) : 667 - 672